{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:42:45Z","timestamp":1792028565776,"version":"4.4.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Platelet-derived growth factor receptor beta (\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    )-rearranged myeloid\/lymphoid neoplasms (MLNs) are rare hematologic malignancies typically responsive to tyrosine kinase inhibitors (TKIs) such as imatinib. However, resistance\u2014particularly in the context of co-occurring high-risk mutations\u2014is uncommon and poorly characterized. We report a case of a 65-year-old man diagnosed with a\n                    <jats:italic>ETV6::PDGFRB<\/jats:italic>\n                    -translocated MLN, presenting as atypical chronic myeloid leukemia (aCML), who exhibited a brief response with development of resistance to imatinib. Although the patient initially achieved hematologic and partial cytogenetic remission, residual fibrosis and cytogenetic abnormalities persisted despite dose escalation. Molecular profiling revealed high-risk mutations in\n                    <jats:italic>ASXL1<\/jats:italic>\n                    ,\n                    <jats:italic>KRAS<\/jats:italic>\n                    ,\n                    <jats:italic>NRAS<\/jats:italic>\n                    ,\n                    <jats:italic>SETBP1<\/jats:italic>\n                    , and\n                    <jats:italic>SRSF2<\/jats:italic>\n                    , along with a variant of uncertain significance (VUS) in\n                    <jats:italic>IDH2<\/jats:italic>\n                    . The patient progressed to acute myeloid leukemia (AML) within 11 months despite sequential therapies including dasatinib and azacitidine-venetoclax, ultimately succumbing to sepsis. This case highlights the limitations of TKI monotherapy in MLNs with\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    rearrangements and co-existing high-risk mutations, underscoring the importance of early molecular profiling and consideration of allogeneic hematopoietic stem cell transplantation in cases with poor risk features.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2025.1611747","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:20:58Z","timestamp":1762492858000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Resistance to imatinib in a ETV6::PDGFRB rearranged myeloid\/lymphoid neoplasm with high-risk mutations: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Lucia","family":"Cavelier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Saft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Deneberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-020-03753-y","article-title":"PDGF receptor mutations in human diseases","volume":"78","author":"Gu\u00e9rit","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27287","article-title":"World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Shomali","year":"2024","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-024828","article-title":"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/his.15021","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases","volume":"83","author":"Saft","year":"2023","journal-title":"Histopathology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24267","article-title":"Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.187302","article-title":"Molecular genetic characterization of myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2","volume":"103","author":"Baer","year":"2018","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01958-1","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort","volume":"37","author":"Metzgeroth","year":"2023","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.250","article-title":"NDEL1-PDGFRB fusion gene in a myeloid Malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors","volume":"31","author":"Byrgazov","year":"2017","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S427995","article-title":"Myeloid\/lymphoid neoplasms with ETV6::PDGFRB fusion gene: A rare case of poor response to imatinib and possible transformation mechanisms from myeloid neoplasms of bone marrow to T-cell lymphoblastic lymphoma invasion in lymph nodes","volume":"16","author":"Gou","year":"2023","journal-title":"J Inflammation Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.09.003","article-title":"Why and how to treat Ph-like ALL","volume":"31","author":"Roberts","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.23257","article-title":"Precision diagnostics in myeloid Malignancies: development and validation of a national capture-based gene panel","volume":"63","author":"Orsmark-Pietras","year":"2024","journal-title":"Genes Chromosomes Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2008.09.012","article-title":"Tel\/PDGFRbeta induces stem cell differentiation via the Ras\/ERK and STAT5 signaling pathways","volume":"37","author":"Dobbin","year":"2009","journal-title":"Exp Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-555607","article-title":"Patients with myeloid Malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2005","article-title":"p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder","volume":"64","author":"Grand","year":"2004","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.301","article-title":"Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene","volume":"30","author":"Ross","year":"2016","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.23","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2241-1","article-title":"Somatic SETBP1 mutations in myeloid neoplasms","volume":"105","author":"Makishima","year":"2017","journal-title":"Int J Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.06.009","article-title":"Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy","volume":"59","author":"Kim","year":"2017","journal-title":"Leuk Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1611747\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:20:59Z","timestamp":1762492859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1611747\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":20,"alternative-id":["10.3389\/fonc.2025.1611747"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1611747","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"article-number":"1611747"}}